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1. INTRODUCTIOI\I 
Many biological processes are initiated by the ac- 
tivitics of proteolytic enzymes [l]- Proccases are under 
the control of a number of protease inhibitors [2]. In 
the central nervous system, important events such as 
neural cell migration during brain development and 
ncurite outgrowth after brain tissue damage have been 
found to depend on a precarious balance between pro- 
teases and their inhibitors [3]. Proteases and their in- 
hibitors may contribute to pathogenic events. In 
Alzhcimer’s disease (AD), proteases and their inhibitors 
seem to be of particular importance: (i) the proteases 
cathepsin B and D [4] as well as the proteinase inhibitor 
alpha I-antichymotrypsin [S] have been found to be 
constituents of AD senile plaques; (ii) two forms 
(APP751 and the APPvo) of the Alzheimer 
@G4-amyloid precursor protein (APP) are Kunitz-type 
proteinase inhibitors [6,7, for reviews see 7,8]; (iii) by 
investigating APP synthesis in cultured cells it has been 
found that secretion of (the large N-terminal part of) 
APP is the result of a proteolytic leavage C-terminal to 
residue 16 of the @A4 part of the mature transmem- 
brane APP [g-13]. 
mation of AD senile plaques 1321. If the above- 
mentioned secretory cleavage of APP inside its @A4 
part [12,13] is part of the normal APP processing, for- 
mation of the PA4 protein would be prevented under 
normal conditions. It appears conceivable that the for- 
mation of the pathogenic DA4 protein in AD may be the 
result of an inhibition of the APP-cleaving Protease 
(which is called secretase). 
We decided to screen cultured human neuronal cells 
for the synthesis of a number of proteinase inhibitors. 
In this communication, we report synthesis of alpha 
Smacroglobulin (a2M), the most potent of the known 
human proteinasc inhibitors [ 141, by interleukin-6 
(H--6)-stimulated neuroblastoma cells. Evidence is pro- 
vided that IL-6-induced a2M synthesis may be involved 
in the pathogenesis of Alzheimer’s disease. 
2. MATERIALS AND METI-IODS 
2.1. Malerials 
In AD, APP is degraded by an unknown mechanism 
to the 42-43 amino acid ,&44 molecc!e which has a high 
tendency to aggregate and thus contributes to the for- 
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RPM1 1640 medium was from Seromed (Berlin, Germany), sup- 
plements (L-glutamine, antibiotics and vitamins) and fetal calf serum 
(FCS) were from Gibco (Karlsruhe, Germany), Purified muriae Nerve 
growth factor p was a generous gift from U. Otten, University of 
Basel, Switzerland. Human recombinant interleukin-6 (Boehringer, 
Mannbeim, Germany) had a specific activity of 2 x 10’ units/mg as 
determined by the 7TDl-hybridoma growth assay, equivalent to 
1 x 10’ units/mg if determined as B-cell stimulatory factor @W%2) 
units. Indication of 12-6 units in this paper refer to BSF-2 units. 
Human alpha 2-macroglobulin was from Boehringer (Mannheim, 
Germany). Retinoic acid and dibutyryl-CAMP were from Sigma 
(Deisenhofen, Germany). Protein-A-Sepharose was from Pharmacia 
Published by Ekevier Science Publishers B, V. IIR I/./ 
The Stl.SYSY nr‘urobhrsmm:~ &we [Ia] wux u gift lrtlm Dr J. 
Bicdlrr, Memorial Slumi-Kellcring Cancer Cwwr Ww York, N,Y,). 
Cells (0,s x 10b/dixli)wcrcyrown on 40mm plnaliu dixhcx (Nurrc, IL.1 
in RPM1 I640 medium/l% FC8 aupplemcn~cd wilh L~~lutamine, an- 
tibioties, and vitamins, Mrlrint? nerve &trowlh factor 8 (NGF d), 
retinoic acid, and dibutyryl ohiCtP (Jb CAMP) wcrc added KI rhc 
nicdium nt a rinal caneenlrn~ion 0r 20 nglml, IO p?~l, nnd 0.5 mhl, 
rrspaxivcly. These somponemr hrrvr been dcrcribtd IO rcsulr in n dir- 
fcrcn~hwzd phenolypc of eulnwcd ncuronal cells [ 17). 
Sl-ISYSY-cells wcrc plated an 0iernitlnox pl:rsric coverslips (Nb~nc, 
IL,) nrvzl cultivated for 5 days as describer\ above. The cnvcrslips were 
then washed with plrosphi~re.bl~ffered snlinc (PBS) and fixed with 4Qte 
formalin/DWj. After incubation with a I:10 dilution of the primary 
antibodies aati.nlpha-tnu or anti alpha~nc~lrofilalncnt 200, cells \WC 
treated with the VWnsu\in ARC-peroxidasc dctcctiun syswm (Vcctur, 
Burlingamc, CA). Cells wcrc mounted in glyccrinpclnrinc (Merck, 
Darnwad!, Germany) nnd vicwcd with a %ciss III RS microscope, 
Radiolabeling and ilniiitlnoprccipitation was done as dcscribcd 
earlier in derail by oursclvcs [IEJ. IWcfly, cells wcrc metabolically 
labeled by replacing media by methionine~ and strum-free RPM1 I640 
medium and addition of [“Sjmcthioninc (100 &i/dish). Cells were 
allowed to incorporate the radioactive amino acid into newly syn- 
thcsired proteins for 4 h. For pulse-chase experiments, cells wcrc 
labeled with 200 pCi/dish for 20 min followed by addition of an cx- 
cess of unlabeled methioninc (2 mM final concentration). For im- 
munoprecipitalion. media were separated from the cells. Cells wcrc 
homogenized in I ml 25 mM Tris-HCl, pH 7.5, 20 mM NaCI, I% 
Narriumdeoxycholate, I % Triton X-100. Non-soluble material was 
removed by centrifugation. Cell homogenates and media were diluted 
with2 volumes of immunoprccipitation buffer (20 mM Tris-HCI, pl-i 
7.6, 0.14 M NaCI, 5 mM EDT& I070 Triton X-100). Total de-novo 
synthesized proteins were determined by TCA-precipitation of 20 )II 
aliquots of cell homogenates and media according to (191. Specific 
proteins were extracted from equivalent amounts of total TCA- 
precipitable radioactivity (usually 0.5 x IO” cpm from media), In the 
case of pulse-chase experiments, specific proteins were extracted from 
total medium and From one third of the cell homogenate. Prior to ex- 
traction with specific antibodies, unspecifically-binding material was 
absorbed by a sham extraction with rabbit non-immune control 
serum. After addition of an excess of antibody (usually 10 rl), the im- 
mune complexes were bound to an excess (7 mg) of Protein A 
Sepharose CL-4B, sedimented. and washed (twice in im- 
munoprccipitation buffer, twice in 50 mM sodium phosphate buffer, 
pH 7.5). The immune complexes were dissociated by treatment at 
95°C for 5 minutes in 35 111 of 0,1 M Tris-HCI, pH 6.8, 5% 
2mercaptoethano1, 5% sodium dodecylsulfate, 10% glycerol, sub- 
jected to sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) according to [20], and fluorography according to [2l]. 
The specific radioactive bands were cut out from the gels, solubilized 
In rheor cclh, w investigated de-naver rynthcsls aF 
alpha Z?-macroglsbulin @2M) by immunepreeipirtlrlan 
from cuhure media nfrer metabolic labeling, All W- 
perinrents were reproduced sII Ic:asf 3 times; typical Iz;t= 
perinrcnrn arc shown, Spontaneous a2M exprcsaian in 
the human ncuronal cwlrurcs was very low: if exprersed 
RS gerrentcsgc of total secreted prarcins, a2M nmeuntcd 
to about O,Ol%, However, de-nsvo synthesis and secrc- 
tion VGI~ drplmtrticl?lly induced upon incubation of the 
neuronnl cells with interlcukin-6 (IL-B) in a time- nnd 
dosedcpcndcnt manner (Fig. 2). Maximally induced 
i12M secretion was observed after R 24 k incubarion time 
with IL-6 in a final concentration of 200 unirs/ml. 
Then, a2M secretion had increased 20 times and now 
amounted lo 0.2% of total secreted proteins, Secrcrion 
on rhis level in IL-Gstimuiated cells persisted for at Icast 
72 h (nor shown). Other inflarnmarory cytokincs such 
as interleukin-la (IL-l), inrerlcukin-2, tumor necrosis 
factor alpha (TNF), gamma interferon, leukemia in- 
hibitory factor (I-IF) or transforming growth factor P 
did not affect a2M synthesis. On the other hand, it-6 
in our ncuronal cells did not induce the synthesis of 
other proteinase inhibitors such as alpha 
l-antichymotrypsin or alpha l-antitrypsin. 
Confirming a previous report [22], our SH.SYSY 
neuroblastoma cultures constitutively expressed 
Alzhcimcr’s /3A4-amyloid precursor protein (APP) as 
shown by a pulse-chase xperiment (Fig. 3). APP is syn- 
thesized intracellularly in several molecular weight 
forms in the range between 98 kDa and 140 kDa (Fig. 
3, lanes 1,5,9). This heterogeneity has previously been 
shown to be due to the facts first that the APP hn 
mRNA is differentially spliced into 3 major mRNA 
forms [6,9,23], and second that the APP protein is sub- 
jected to intracellular processing including Iv-, O- 
glycosylation, and thyorosine sulfation [I I]. Secretion 
‘of the major N-terminal part of APP is achieved by 
proteolytic cleavage of the mature transmembrane APP 
molecule [12] resulting in secreted APP forms in the 
molecular weight range between 98 kRa and 123 kDa 
(Fig. 3, lanes 4,8,12). Treatment of the neuronal cells 
with IL-6 for up to 3 days did neither affect APP syn- 
thesis nor its secretion (Fig. 3, lanes 4-8 compared to 
lanes 1-4). Treatment of the cultures with exogenously 
added a2M slightly affected intraceliular a2M synthesis 
(78% of control after standardization with respect to 
total protein synthesis). However, APP secretion was 
strongly inhibited (17% of control). 
Fig. 1. tvlorphological chnrncrerizarion 0r culrurcd I~I~PII ncuronnl (SW-SYSY neuroblastomo) cells, Murirnn SWSYSY nCl~rOblilSlOllla cells wcrc 
PtWd on plnslic covcrslips and cullivnrett for 5 days nr describctl in section 2. Crlls were washed, fixed, subjcckxl 10 in~~nunohistochcrnical peros- 
tkc staining wilh anti-alptul-rau (A) or ;lnli.nculofi’dlncnt 200 antibody (13). and viewed (magnification x 375). Control stains wilh non-immune 
s( ra show4 no staining at all (not stlOWl1). 
4. DISCUSSION 
We found strong induction of alpha Zmacroglobulin 
(a2M) synthesis in cultured human ncutonal cells upon 
stimulation with interleukin-6 (IL-6). If a2M was ex- 
Ogenously added to cultured neuronal cells, synthesis of 
Alzheimer’s @A4 amyloid precursor protein (APP) was 
slightly repressed, however, APP secretion which re- 
quires a proteolytic cleavage of APP by a still unknown 
protease (secretase) was strongly repressed. Since IL-6 
could induce a2M secretion in the cultured cells, and, 
on the other hand, a2M could affect APP synthesis and 
secretion, one would expect that treating the cultures 
with IL-6 should have an indirect effect on APP syn- 
thesis and secretion. Mowever, a2M secreted into the 
culture medium by IL-6-stimulated cells reaches con- 
centration magnitudes below that of exogenousiy added 
a2M which was 1 mg/ml, similar to a2M serum concen- 
trations (1.3 m&ml). We recently observed marked 
a2M immunoreactivity in large neurons and in senile 
plaques of AD brains (B. Volk, J. Bauer, in prepara- 
tion). If in fact a2M synthesis and secretion is turned on 
in vivo, local pericellular a2M concentrations in the 
brain may well reach significant concentrations. 
Our findings could be of considerable biological 
significance. IL-6 is one of several inflammatory 
cytokines which are synthesized by the host upon injury 
or infection [M-263. Along with TNF and IL-l, this 
mediator initiates a complex reaction of the host called 
acute-phase response. In addition to demonstrating for 
the first time a2M synthesis by neuronal cells we pro- 
vide evidence that, at least in the central nervous 
system, human a2M may behave as a cytokine- 
inducible acute-phase protein, Outside the CNS, human 
a2M is constitutively present in the serum (serum con- 
centration I.2 mg/ml [27]) and does not behave as an 
acute-phase reactant [28]. Until no&, systemic acutc- 
phase properties of a2M have only been described in the 
rat [29,30]. 









Pig. 2, Induction of alpha 2.macroglobulin synthesis in human 
ncuronal cells by intcrlcukin.6. Human SHZWY ncuroblttstoma 
cells (0,s x IO* ecllsI4O mm dish) were cultivated for 5 days as dcrcrib- 
cd in section 2. (A) Human rreomblnant intcrlcr:kin-6 (10 units/ml) 
was added to rhc cultures for 6 (lane 3), 12 (lane 4), or 24 h (Inncs S,(5) 
prior to metabolic labclling of the cells, Cell5 kept in the abrcnce of 
intcrlcukin-6 served as control (lnnr 2), (R) Alternatively, cells were 
trcntcd for 24 h withdiffcrcnt conccntrationsof intcrleukin-6: control 
(lane 1). 1 unit/ml (lane 2), IO units/ml (lane 3), 100 units/ml (lane 
4), 200 units/ml (lane S), 400 units/ml (lane 6). Cells from (A) and (8) 
were metabolically l3bclcd for 4 h by rcpl3cing media with strum- and 
mcthioninc free RPMI.medium containing 100 &i [‘sS]methioninc/ 
dish. Alpha 2.macroglobulin wns irnmunoprecipitatcd from com- 
parable amounts of TCA-prccipitablc radioactivity from the culture 
tncdia, subjected to SDS-PAGE and autoradiography 3s detailed in 
section 2. Preabsorption of unspecifically bound material by non. 
immune control serum is shown in (A), lane 1. Displaccmcnt of 
radiolabcled alpha 2-macroglobulin by addition of Xl c(g unlabeled 
alpha 2.macroglobulin to the medium prior to immunoprccipitation 
is shown in (A), larle 6 (compared to lane 5). 
[14,28]. By balancing the amazing variety of en- 
dogsgous proteases, protease inhibitors control impor- 
tant proteolytic functions such as coagulation and 
fibrinolysis, activation of the complement system and 
tissue breakdown. In the central nervous system, 
neurite outgrowth has been found to depend on a 
precarious balance between proteases and protease in- 
hibitors at and around the neuritic growth cones [3]. 
IL-6 can be produced in the central nervous system by 
microglia and astrocytes under inflammatory condi- 
tions [3 l], Therefore, it could be that IL-6 induced a2M 
synthesis may affect neuronal plasticity under inflam- 
matory conditions. 
Impaired APP secretion in the presence of a2M could 
point to a potential inhibition of the proteolytic 
cleavage which is necessary for the release of the 
secretory part of the APP molecule. It has previously 
been shown that the intracellularly synthesized mature 
APP protein is inserted into the cell membrane [la] 
130 
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Fig. 3. /IA4 Amyloid precursor protein (APP) synthesis and secretion 
by human ncuronal cell cultured in the absence (lanes l-4) and 
presence of intcrlcukin.6 (lanes S-8) or alpha 2~m3croglobulln (lanca 
g-12), Humnn SIGSYSY neuroblnstomtt cells (IO’ ccllnN0 mm dish) 
were cultivated for 5 days as described In section 2. For an additional 
72 h, cells were either incubated 3s before (lanes l-4), or In the 
prcscncc of 200 units hr intcrlcukinV6 (Innes S-g), or the prcscncc of 
algha 2.macroglobulin in a final concentration of I mg/ml (lanes 
9-12). Ear metabolic pulse-labclling, media wcrc replaced by scrum- 
and methioninc.frcc RPM1 1640 medium containing 20 fiCi 
[“S]methioniae/dish. After 20 rnin, cells wcrc cithcr harvested im- 
mediately (lanes 1,3,5,7,9,1 I), or radiolabclled rncthioninc was chns- 
ed by an cxccss of unlabeled rncthioninc (2 mM final concentration) 
for 4 h (lanes 2,4,6$,10,12). Cultures were harvested by separating 
media from cells. /3APP was immunoprccipltated from one third of 
the cell homogenates (lanes 1,2,5,8,LO) and from total culture media 
(lanes 3,4,7,&l 1,12), subjected to SDS-PAGE nnd autoradiography 
as described in section 2, Prcabsorption of unspecifically bound 
material by non.immunc control serum is shown in PC (for cell 
homogenates) and Pm (for media). Total de-novo synthesized in- 
tracellular proteins (determined as TCA-prccipitable cpm) at the end 
of the pulse labeling (i.e. 0 h of chase) was 3.17x IO* cpm in control 
cells; 3,09x 106cpm in IL-&treated cells; and 2.22 x Id cpm in 32M- 
treated cells. Total de.novo synthesized and secreted proteins after 4 
h chase (determined as above) amounted to IIll x lo6 cpm (Co), 
1.19x IO6 cpm (IL&), and 1,13x IO” cpm (a2M). If, after standar. 
dization with respect to total protein synthesis/secretion, intracellular 
(0 h chase) APP and secreted APP (4 h chase) in a2M-treated cultures 
was compared to controls, then intracellular a2M was reduced by 
22% and secreted a2M by 83%. 
followed by cleavage of APP resulting in secretion of 
the large N-terminal APP portion. This cleavage hap- 
pens inside the @A4 sequence of the APP protein, C- 
terminal to residue 16 of the BA4 part of APP [l%, 131. 
Thus, unaltered APP cleavage by the still unknown 
protease (called secretase) prevents the formation of the 
PA4 protein which is found as a main component of the 
cortical senile plaques in Alzheimer’s disease [32]. It 
must be assumed that inhibition of the still unknown 
protease/secretase is part of the pathophysiological 
ev~nto in Al~hciner”a dixcnta Purthcr studies AI% under 
way t6 exactly rdate the antipratealytic pmntial BP 
a%4 to its effecta m APP praccnxing (b. Sottrup 
Jenrcn, J. Bwuer, in prcprration), 
A~‘knrrv/~r/#rrrtcrrra: This work wad rupporuxt by gramx from lhc 
Dculrchc ForszhungsU~nlcinscholr (J.B, by SFB 154; K.13, by St% 
317) nntt from the Frirx Thyxrefl S~iftung (J,B,I, 
REFERENCES 
[II Ncurnth, W. (1984) Science 224, 350-357. 
[2’] Trnvir, J. and Salvesen, Ci.S, (1983) Ann, Rev, Biechem. 52, 
655-709, 
[3] Monnrd, t3, (1988) Trends Neural. Sci. II, 541-544, 
[4] Cataldo, A.M. and Nixon, R,A. (1990) Proc Nell. Acad. Sri. 
USA 87, 3861-3865, 
(S] Abraham, CR., Sclkoo, D,J. and Porter, fi, (1988) Cclt 112, 
487-501 I
[6] Kitaguchi, N,, Takahasi, Y.,Tokushima, Y,, Shiorjiri, S. and 
ito, H, (1988) Nerurc 33t, 530-532. 
[6j Olrcrsdorf, T., Fritz, L.C., Schcnk, D,B,, Licbcrburg, I., 
Johnsan~~Wood, K.L,, Beatlic, EC,, Ward, P-J,, Rtnchcr, 
R.W., Dovcy, PI,F. and Sinha, S. (1989) Namre 341, 144-147. 
[7] Miillcr-Hilt, B. and Bcyrcuthcr, K. (1989) Ann. Rev. Riochem. 
58, 287-307. 
(81 Sclkoe, D.J. (1990) Science 248, 1058-1060. 
[9] Kang, J., Lcmairc, H.G., Untcrbcck, A,, Salbeum, J,M., 
Masters, C.L.. Grzcschik, K-H,, Mutthaup, G., Bcyrcuthcr, K. 
and MLltlcr~Hill, 8. (1987) Nnture 325, 733-736. 
[IO] Dyrks, T., Wcidemann, A., Multhaup, G., Salbnnm, J.M., 
Lemairc, H,Ci,, Kane, J., Miillcr-Hill, B,, Master. C.L. and 
Bcyreulher, K. (1988) EMBO J, 7, 349-957. 
[11) Weidemann, A., Kanig, G., Bunke, D,, Fischer, P,, Salbaum, 
J.M., Master, C.L. and Beyrcuthcr, K, (1989) Cell 57, 115-126. 
1141 Borrrup&nun, I,. (IBIY) J, Uiat. Ck@m, 264, t1539~tlfd2, 
[IS) e;i%nlor, Wz, @dluer, J., Jehutx.Huur~rrt, C., ~tibiekr.Hrer~or, 
P.J., ffrsrcsr, H. and GcIc~~, W. (1987) Eur. 1, Rioelrmm, 169, 
r3-20, 
(16) Wirdtor, J-b,, Kafflcr-T#rlw, !I%,, khachnrr, hl. and Fr~ettm#n, 
LY. (1987) C#nol$r 812%. 38, 375k”37$7, 
It71 Botrccnrlrin, J.E. tl98t) In: Func0onatty f3iffetcnttnied Cot1 
Llncs, Alan W. L&L, New York, pp, I$$-184. 
ItRl Bluer, J,, Kurtlowrkct, A., Trrn.Xhlc, T.A., Rudck, W., Koj, 
A., Drlcker, K. and Helnrich, PC. (I 985) Eur. J, Btochsm. 146, 
347-352. 
1191 M#ns, R.J. and Novctli, Ci,D, (1961) Arch. Btochom. Biophys. 
94, p, 48. 
(201 Kin& I. and I.4mmlt, bl. (1971) J. Mot, Biot. 62, 465-473. 
1211 Wonncr, J. nnd b#skcy, R.A. (l974)Eur. J. Biochcm. 46,83-R& 
i22l Kbnir, C., Master, C,L. and Beyreulher, K. (19901 FED% Lerr. 
269, 365-310. 
[23) Pen% P., Gonmlcr~DcWhirr, P., Schitling, J,, Miller, J., Hsu, 
D., Grrcnbcrg, B., Davin, K., Wallace, W., Licbcrburg, I., 
Fuller, F. and Cord&l, B, (1988) Na~urc 331, 523-527, 
1241 Baucr, J,, Ganrcr, U., Gcigcr, T., Jacobshagcn, U,, Hirano, T., 
Marsuda, T., Kirhtmo[o, TF,, Andur, T., Aes, G., Gcrok, W. zmd 
Cilibcrlo, 6. (l988} Blood 72, I 134-l 140. 
1251 Baucr, J., Baucr, T-M., Kelb. T., Tq$a, T., Lcngyel, G,, 
Hirano, T,, Kishimolo, T., Acs. G,, Moyer, 1. and Gerok, W. 
(1989) Jd Exp. Med. 170, 1527-1549. 
[26] Bluer, J. (1989) Klin. Wochenschr. 67,697-706. 
(271 Coan, M.H. and Roberts, R.C. (1989) Biol, Chsm. 
Hoppc-Scylcr 370, 673-676. 
[2X] Van Leuvcn, F. (1982) Trends Bioohcm. Sci. 7, 185-187. 
[29] Baucr, J., Birmetin, M,, Nortkoff, G-H., Northcmnnn, W., 
TranmThie, T-A,, C)berbcrg, I-I,, Decker, K. and Hcinrich, PC. 
(1984) FEDS LEII. 177, RB-94. 
[30] Northcmnnn, W., Shicls, B.R., Braciak, T.A,, Hanson, R.W., 
Heinrich, P.C. and Fey, G. (1988) Biochemistry 27, 9194-9203. 
[31] Frei, K.. Melipicro, U.V,, Lcist, T.P., Zinkcrnnycl, R.M., 
Schwab, M,E. and Fontana, A. (1989) Eur. J. Immunol. 19, 
689-694 
1321 Mnstcrs, C.L., Simms, G., Wcinman, N.A., Mulrhaup, G.. 
McDonald, 13.L. and Bcyreuthar, K. (1985) Proc, Nat]. Acad. 
Sci. USA 82, 4245-4249. 
